Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epoprostenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | PPARD | Q03181 | 1/20 | 0.58 |
| ▸ | PPARA | Q07869 | 1/20 | 0.58 |
| ▸ | PTGFR | P43088 | 5/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epoprostenol SCHEMBL4299219 | 1.00 | ALDH1A1 (0.82) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL41344 | 1.00 | ALDH1A1 (0.82) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL29121502 | 1.00 | ALDH1A1 (0.82) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL5452422 | 0.96 | ALDH1A1 (0.90) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL24612535 | 0.90 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL551617 | 0.90 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL8041 | 0.90 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL24033081 | 0.90 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL21283002 | 0.90 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL22607961 | 0.90 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161220-A1 | LYMPHATIC DELIVERY OF NANOPARTICLES TO TREAT NEURODEGENERATIVE, NEUROLOGICAL, AND EYE CONDITIONS | THE CLEVELAND CLINIC FOUNDATION | 2025-05-22 | — | — | US | claimed |
| EP-4479029-A2 | LYMPHATIC DELIVERY OF NANOPARTICLES TO TREAT NEURODEGENERATIVE, NEUROLOGICAL, AND EYE CONDITIONS | The Cleveland Clinic Foundation (US) | 2024-12-25 | — | — | EP | claimed |
| US-20230310478-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION AND CANCER | ZHAO, Youyang | 2023-10-05 | — | — | US | claimed |
| WO-2023159114-A2 | LYMPHATIC DELIVERY OF NANOPARTICLES TO TREAT NEURODEGENERATIVE, NEUROLOGICAL, AND EYE CONDITIONS | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-08-24 | — | — | WO | claimed |
| US-11714094-B2 | Composition comprising prostacyclin andor analogues thereof for treatment of acute critically ill patients | ENDOTHEL PHARMA APS (DK) | 2023-08-01 | — | — | US | claimed |
| WO-2022051495-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION AND CANCER | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO (US) | 2022-03-10 | — | — | WO | claimed |
| EP-3278112-B1 | A COMPOSITION COMPRISING PROSTACYCLIN OR ANALOGUES THEREOF FOR TREATMENT OF ACUTE CRITICALLY ILL PATIENTS | ENDOTHEL PHARMA APS (DK) | 2021-09-22 | — | — | EP | claimed |
| US-20200352155-A1 | SYSTEMS AND METHODS FOR EX VIVO LUNG CARE | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2020-11-12 | — | — | US | claimed |
| US-10750738-B2 | Systems and methods for ex vivo lung care | TRANSMEDICS, INC. (US) | 2020-08-25 | — | — | US | claimed |
| US-20200217857-A1 | COMPOSITION COMPRISING PROSTACYCLIN ANDOR ANALOGUES THEREOF FOR TREATMENT OF ACUTE CRITICALLY ILL PATIENTS | ENDOTHEL PHARMA APS (DK) | 2020-07-09 | — | — | US | claimed |
| EP-1942726-A2 | SYSTEMS AND METHODS FOR EX VIVO ORGAN CARE | Transmedics, Inc. (US) | 2008-07-16 | — | — | EP | claimed |
| US-20080017194-A1 | Systems and methods for ex vivo organ care | TRANSMEDICS, INC (US) | 2008-01-24 | — | — | US | claimed |
| WO-2007124044-A2 | SYSTEMS AND METHODS FOR EX VIVO ORGAN CARE | TRANSMEDICS, INC. (US) | 2007-11-01 | — | — | WO | claimed |
| US-20070167472-A1 | 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide; vasoconstrictor, mediator of cardiac, renal, endocrine functions; neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and differentiation | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-19 | — | — | US | claimed |
| WO-2005110494-A2 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF THROMBUS FORMATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-11-24 | — | — | WO | claimed |
| WO-2005021006-A1 | METHOD AND SUBSTANCE FOR FACILITATING WEANING, REDUCING MORBIDITY AND REDUCING MORTALITY IN CARDIAC SURGERIES INVOLVING EXTRA-CORPORAL CIRCULATION | INSTITUT DE CARDIOLOGIE DE MONTRÉAL (CA) | 2005-03-10 | — | — | WO | claimed |
| US-20050049174-A1 | Method and substance for facilitating weaning, reducing morbidity and reducing mortality in cardiac surgeries involving extra-corporal circulation | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2005-03-03 | — | — | US | claimed |
| US-20040180812-A1 | Methods of treating and preventing proliferative disease | TECHNOLOGY CENTER | 2004-09-16 | — | — | US | claimed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | APOB, MMAB, CBS | PTGIR 253/4885ALDH1A1 2724/4885MEN1 118/4885 |
| US-20230310478-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION AND CANCER | TOP2A, TOP2B, TOP1 | PTGIR 770/4885ALDH1A1 1745/4885MEN1 704/4885 |
| US-20070167472-A1 | 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide; vasoconstrictor, mediator of cardiac, renal, endocrine functions; neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and differentiation | EDNRA, EDNRB, AGTR2 | PTGIR 24/4885ALDH1A1 806/4885MEN1 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.